TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04437914

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram diagnosis
Description: Electrocardiographic diagnosis will be made in a double-blind manner by two specialists in cardiology and cardiac arrhythmias and the results will be compared between the groups studied.
Study: NCT05713110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tazemetostat
Description: Dose Escalation Phase (Phase IIa):~Tazemetostat (800 mg BID orally) in a therapeutic cycle of 28 days;~Dose Expansion Phase (Phase IIb):~Tazemetostat (800 mg BID orally) in a therapeutic cycle of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-689
Description: Dose Escalation Phase (Phase IIa):~HMPL-689:20 mg and 30 mg, QD orally in a therapeutic cycle of 28 days.~Dose Expansion Phase (Phase IIb):~HMPL-689 (RP2D) in a therapeutic cycle of 28 days
Study: NCT05294042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Navigation
Description: The intervention in this study is a model of navigation for families seeking services at the two mental health agencies collaborating on this study. Navigators will implement a model of navigation with caregivers focused on reducing logistical and attitudinal barriers to care.
Study: NCT06040086

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously, equivalent volume to tozorakimab throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozorakimab
Description: Administered subcutaneously tozorakimab and placebo throughout the study.
Study: NCT06349616

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intermittent cold-water hand and forearm immersion
Description: Participants will be seated at rest in a hot and humid environment. At 2 time points in the experiment, participants will place their hands and forearms in a bucket of cold tap water for 10 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent cold-water hand and forearm immersion
Description: Participants will be seated at rest in a hot and humid environment. At 2 time points in the experiment, participants will place their hands and forearms in a bucket of cold tap water for 10 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intermittent cold-water hand and forearm immersion
Description: Participants will be seated at rest in a hot and humid environment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intermittent cold-water hand and forearm immersion
Description: Participants will be seated at rest in a hot and humid environment.
Study: NCT04947397

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pupillometry
Description: Pupillometry prior to extubation
Study: NCT05864313

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: 10 Hz rTMS for 5 seconds over the frontal eye fields with 25 second intertrain interval for 10 trains (500 pulses) at 90% of the resting motor threshold,

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gait training
Description: Subjects will practice stepping on virtual targets with real-time feedback of their foot position displayed on a screen while walking on a treadmill.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Gait training
Description: Subjects will practice stepping on virtual targets with real-time feedback of their foot position displayed on a screen while walking on a treadmill.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gaze training
Description: Subjects will perform gaze stabilization and gaze shifting exercise via a virtual reality headset.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Gaze training
Description: Subjects will perform gaze stabilization and gaze shifting exercise via a virtual reality headset.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham rTMS stimulation will produce discharge noise and vibration without stimulating the cerebral cortex.
Study: NCT03329157

Intervention type: OTHER
Group type: OTHER
Intervention: Rebuilding Bridges
Description: Psychosocial intervention to help veterans re-engage with family members called Rebuilding Bridges, developed for this project.
Study: NCT05888792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Variant of Defocus Incorporated Spectacle lens (DG2)
Description: DG2 is a variant of Defocus Incorporated Spectacle lens that corrects the distance refraction and provides myopic defocus simultaneously
Study: NCT05035407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2 (Aldesleukin)
Description: dose of 720,000 IU/kg (based on total body weight) as an intravenous bolus over a 15 minute period beginning within 24 hours of cell infusion and continuing for up to four days (maximum 12 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 30 mg/kg IV infusion over 1 hour (+ 10 min) Once daily x 2 doses (Days -6 and -5)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KK-LC-1 TCR
Description: 1 x 108 transduced KK-LC-1 TCR T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2 IV infusion over 30 minutes (+ 10 min) To be administered following completion of cyclophosphamide. Once daily x 5 doses (Days -6, -5, -4, -3, -2)
Study: NCT05145192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COSMED K5 CPET (Cardiopulmonary Exercise Test)
Description: In this randomized crossover trial of eligible adults, we will compare peak measurements of oxygen consumption (VO2) and carbon dioxide production (VCO2) during three maximal cardiopulmonary stress exercise tests (CPET), each seven to ten days apart. Subjects will be randomized into either the K5 or ParvoMedics (PM) group for their first CPET using a 1:1 randomization scheme and will serve as their own control in the subsequent test seven to ten days after the previous one. After both a K5 and a PM CPETs have been completed, the participants will complete an additional K5 CPET for test-retest reliability. A within-subjects analysis will be performed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: COSMED K5 CPET (Cardiopulmonary Exercise Test)
Description: In this randomized crossover trial of eligible adults, we will compare peak measurements of oxygen consumption (VO2) and carbon dioxide production (VCO2) during three maximal cardiopulmonary stress exercise tests (CPET), each seven to ten days apart. Subjects will be randomized into either the K5 or ParvoMedics (PM) group for their first CPET using a 1:1 randomization scheme and will serve as their own control in the subsequent test seven to ten days after the previous one. After both a K5 and a PM CPETs have been completed, the participants will complete an additional K5 CPET for test-retest reliability. A within-subjects analysis will be performed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ParvoMedics CPET
Description: ParvoMedics CPET

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ParvoMedics CPET
Description: ParvoMedics CPET
Study: NCT06535997

Intervention type: OTHER
Intervention: Questionnaire
Description: For patients alive only at the time of inclusion, completion of a quality-of-life questionnaire and a medico-economic interview (prospective).
Study: NCT06096272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augment Reality Exergames
Description: Adaptive physical activity AR gaming modules were created in collaboration with physical therapists with expertise in CP and the Augment Therapy app development team. The program will consists of 5 games adapted for children with cerebral palsy.
Study: NCT05866627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afimetoran
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afimetoran
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afimetoran
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afimetoran
Description: Specified dose on specified days
Study: NCT06495996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous mechanical thrombectomy (PMT)
Description: Percutaneous mechanical thrombectomy (PMT) is the endovascular removal of thrombus by catheter-based mechanical or aspiration methods. The term PMT generally describes interventional procedures performed without the use of lytic agents and frequently involves instrumentation in extensive amounts of fresh thrombus.
Study: NCT05842070

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-Intensity Egg Freezing Protocol
Description: The low-intensity egg freezing protocol involves fewer ultrasounds, bloodwork and injections, contributing to a lower cost. Otherwise, this protocol does not differ significantly from the other routine high-intensity clinic protocols.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Egg Freezing Protocol
Description: The high-intensity egg freezing protocol is a routinely used clinic protocol where patients are coming for frequent ultrasounds and bloodwork, as well as more injections, contributing to a higher overall cost for egg-freezing.
Study: NCT06561958

Intervention type: DRUG
Intervention: REKOVELLE
Description: Individualised dosing regiment of REKOVELLE in routine clinical practice.
Study: NCT06560476

Intervention type: OTHER
Intervention: Data collection
Description: Subject's data will be collected from patients that are undergoing care using the Optilume drug-coated catheter system.
Study: NCT06517628

Intervention type: OTHER
Intervention: Purely observational study on the care and outcomes of participants with cardiovascular disease in pregnancy.
Description: The primary exposure variable is the organization of cardio-obstetrics care which will be defined by annual site surveys and its association with outcomes will be defined by hierarchical models adjusting for patient characteristics.
Study: NCT06134154

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopic insufflation gas
Description: Carbon dioxide gas versus air for endoscopic insufflation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoscopic insufflation gas
Description: Carbon dioxide gas versus air for endoscopic insufflation
Study: NCT06289166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0601 for Injection
Description: A Multiple-dose Design to Evaluate the Safety, Tolerability and Efficacy of STSP-0601 for Injection in hemophilia A or B patients with inhibitor.
Study: NCT05877963

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Administered as an IV infusion.
Study: NCT04069013

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCNL
Description: Patients receive standard of care treatment for their urolithiasis using one of two surgical procedures, either standard PCNL or Mini-PCNL

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCNL
Description: Patients receive standard of care treatment for their urolithiasis using one of two surgical procedures, either standard PCNL or Mini-PCNL
Study: NCT05433454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outreach From Navigators
Description: Navigators are professionals who can provide one-on-one assistance with the Medicaid renewal process. The nature of the outreach will be randomized to participants.
Study: NCT05258682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromelains
Description: Bromelain combined with Acetylcysteine (BromAc), administered simultaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: Bromelain combined with Acetylcysteine (BromAc), administered simultaneously.
Study: NCT06218771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3454 Tablets
Description: TQB3454 Tablets is a selective isocitrate dehydrogenase 1 (IDH1) mutation inhibitor
Study: NCT05433454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outreach From Navigators
Description: Navigators are professionals who can provide one-on-one assistance with the Medicaid renewal process. The nature of the outreach will be randomized to participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outreach From Navigators
Description: Navigators are professionals who can provide one-on-one assistance with the Medicaid renewal process. The nature of the outreach will be randomized to participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outreach From Navigators
Description: Navigators are professionals who can provide one-on-one assistance with the Medicaid renewal process. The nature of the outreach will be randomized to participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outreach From Navigators
Description: Navigators are professionals who can provide one-on-one assistance with the Medicaid renewal process. The nature of the outreach will be randomized to participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outreach From Navigators
Description: Navigators are professionals who can provide one-on-one assistance with the Medicaid renewal process. The nature of the outreach will be randomized to participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outreach From Navigators
Description: Navigators are professionals who can provide one-on-one assistance with the Medicaid renewal process. The nature of the outreach will be randomized to participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outreach From Navigators
Description: Navigators are professionals who can provide one-on-one assistance with the Medicaid renewal process. The nature of the outreach will be randomized to participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outreach From Navigators
Description: Navigators are professionals who can provide one-on-one assistance with the Medicaid renewal process. The nature of the outreach will be randomized to participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outreach From Navigators
Description: Navigators are professionals who can provide one-on-one assistance with the Medicaid renewal process. The nature of the outreach will be randomized to participants.
Study: NCT05737121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNX001
Description: VNX001 (alkalinized lidocaine HCl and heparin sodium)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo for VNX001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Alkalinized lidocaine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Alkalinized heparin sodium
Study: NCT05608356

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: injectable platelet rich fibrin(i-prf)
Description: I-prf is a second-generation PRP where autologous platelets and leukocytes are present in a complex fibrin matrix and can be obtained from blood using low-speed centrifugation without adding anticoagulants.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Description: Sham injection as a placebo injection
Study: NCT05898568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: In addition to the routine hand rehabilitation programs for 4 weeks, 5 days, 40 minutes a day, 20 sessions (4 weeks, 5 days a week, 20 minutes) virtual reality based movement therapy program will be applied.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine treatment
Description: 20 sessions (4 weeks, 5 days a week, 60 minutes) routine hand rehabilitation program will be applied.
Study: NCT03803566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pegboard practice
Description: Practice of the grooved pegboard test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pegboard practice
Description: Practice of the grooved pegboard test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Force control practice
Description: Practice performing steady muscle contractions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Force control practice
Description: Practice performing steady muscle contractions
Study: NCT06088771

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab will be administered at the recommended initial dosage of 600 mg (two 300 mg injections) on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab will be administered at the recommended dosage of 350 mg, as an intravenous infusion, over 30 minutes on Day 1.
Study: NCT05450770

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow fever vaccination (STAMARIL)
Description: Yellow fever vaccination (STAMARIL) for HIV positive and negative subjects

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Yellow fever vaccination (STAMARIL)
Description: Yellow fever vaccination (STAMARIL) for HIV positive and negative subjects
Study: NCT05624931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief CBT-Based Intervention
Description: Aims 1 (n=30) and 2 (n=18) will inform the Aim 3 intervention. We anticipate that the intervention will be comprised of four treatment sessions. These sessions will likely target two pathways to PrEP adherence and persistence: (1) decreased withdrawal and avoidance and (2) behavioral skill building to increase self-care/health behaviors. To decrease withdrawal and avoidance, we will likely include CBT-based exercises that improve distress tolerance and coping. To help participants build new behavioral skills, we will likely incorporate behavioral activation and problem-solving. Behavioral activation is a CBT strategy that promotes scheduling activities that align with an individual's values, which will also break maladaptive patterns of withdrawal and avoidance. Problem-solving is an empirically-supported treatment for depression; training patients to problem-solve adaptively will help them approach PrEP use by navigating barriers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual
Description: This is the control intervention. Participants will receive antenatal care as usual, which is monthly visits to the MOU, information about using PrEP during pregnancy (information sheet or pamphlet), and a psychological services referral.
Study: NCT05805475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endotracheal suctioning with expiratory pause
Description: Perform closed endotracheal suctioning with an expiratory pause of 5 seconds

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal suctioning without expiratory pause
Description: Perform closed endotracheal suctioning without expiratory pause
Study: NCT06251921

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restoration
Description: with resin-based composite

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restoration
Description: with resin-based composite
Study: NCT05582629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JT001
Description: JT001 administered orally in tablet form every 12 hours for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days
Study: NCT05335655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine injection
Description: IV initial bolus and trans operative dexmedetomidine infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% infusion
Description: IV initial bolus and trans operative infusion of 0.9% saline solution.
Study: NCT05207202

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electrical impedance tomography
Description: PEEP titrated by EIT will be performed with a decremental trial at the enrollment. Right after completing RM, PEEP will be set to 20cmH2O and then reduced in steps of 2cmH2O from 20 to zero every 2min.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electrical impedance tomography
Description: PEEP titrated by EIT will be performed with a decremental trial at the enrollment. Right after completing RM, PEEP will be set to 20cmH2O and then reduced in steps of 2cmH2O from 20 to zero every 2min.
Study: NCT06303206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Telemonitoring (HBPT) + Case Management (CM)
Description: Home Blood Pressure Telemonitoring (HBPT) includes used of an app to collect and transmit blood pressure readings.~Case Management (CM) includes pharmacists reviewing BP data and providing counselling to participants based on their BP values.
Study: NCT06009679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 200mcg Tab
Description: Patients in the intervention group with suspected postpartum RPOC will receive 600 micrograms of misoprostol up to 3 times following delivery and followed up by ultrasound and clinical examinations for 6-12 weeks post-partum
Study: NCT05116254

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: AZD1390 + radiotherapy
Description: AZD1390 combined with preoperative radiotherapy

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: AZD1390 + durvlaumab + radiotherapy
Description: AZD1390 combined with durvalumab and preoperative radiotherapy
Study: NCT05205980

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Perturbation training
Description: Participants will experience repeated perturbations mixed with non-perturbed trials on the treadmill with the protection by a harness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perturbation training
Description: Participants will experience repeated perturbations mixed with non-perturbed trials on the treadmill with the protection by a harness.